Novel therapeutic approaches for targeting tumor angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tumor angiogenesis, the formation of new blood vessels to feed tumors, is a critical process in cancer progression.
• Current anti-angiogenic therapies primarily target the vascular endothelial growth factor (VEGF) and its receptors (VEGFR).
• These therapies, while effective, often exhibit limited specificity, leading to off-target effects and increased toxicity.

Purpose of the Study:

• To review established and novel molecular targets for anti-angiogenic therapy.
• To discuss the therapeutic benefits and challenges associated with targeting these angiogenic factors.
• To provide an overview of emerging strategies in antivascular therapy for cancer.

Main Methods:

• Literature review of current research on tumor angiogenesis and anti-angiogenic therapies.
• Analysis of established and novel angiogenic molecules and their signaling pathways.
• Evaluation of therapeutic approaches targeting these molecules.

Main Results:

• The VEGF-VEGFR pathway is a well-established target, but its inhibitors lack specificity, causing toxicity.
• Several novel angiogenic molecules have been identified as potential therapeutic targets.
• Targeting these factors offers potential for more specific and less toxic antivascular therapies.

Conclusions:

• While VEGF-VEGFR inhibitors have clinical utility, their lack of specificity necessitates exploration of alternative targets.
• Emerging angiogenic molecules represent promising candidates for developing next-generation antivascular cancer therapies.
• A deeper understanding of angiogenesis pathways can lead to more effective and safer treatments for various cancers.